Toxicity and prognosis in overweight and obese women with lung cancer receiving carboplatin-paclitaxel doublet chemotherapy.
We retrospectively analyzed overdosing-related toxicity and prognosis in 127 women with lung cancer receiving carboplatin (6AUC) estimated by the Cockcroft-Gault formula using actual body weight and paclitaxel (200 mg/m(2)). Between the body mass index (BMI) > 25 group (n = 42) and the BMI ≤ 25 group (n = 85), there was no difference in dose intensity of carboplatin (122 mg/m(2)/week vs. 124 mg/m(2)/week, p = .323), median overall survival (285 days vs. 282 days, p = .820), and toxicity, except Grade 4 neutropenia in the second cycle. Women with BMI > 25 did not have an increased risk of toxicity because of an appropriate dose reduction.